ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy boosts Chemo-Radiation in esophageal cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with advanced esophageal cancer live longer without the disease getting worse. About 700 participants who cannot have surgery will receive either pembrolizumab …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 05:01 UTC
-
Belly radiation plus immunotherapy may turn inoperable esophageal cancer into a surgical candidate
Disease control OngoingThis study tests whether a low dose of radiation to the intestine, combined with immunotherapy (tislelizumab) and chemotherapy, can shrink borderline or unresectable esophageal cancer enough to allow surgery. About 43 adults with a specific type of esophageal cancer will receive …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated May 26, 2026 05:01 UTC
-
Hidden cancer spread: new study maps invisible tumor edges
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at tissue samples from 30 people who had surgery for esophageal cancer. Researchers want to measure how far cancer cells spread beyond the visible tumor edge. The goal is to better understand hidden cancer growth patterns, which could help improve future surgerie…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Shanghai Chest Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 05:10 UTC
-
French study tracks Real-World survival of nivolumab combo for stomach cancer
Knowledge-focused OngoingThis study follows 208 adults in France with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer who are receiving nivolumab combined with chemotherapy as their first treatment. The main goal is to see how long patients live in real-world conditions. R…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC